NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

視黃酸受體Alpha:開發中產品分析

Retinoic Acid Receptor Alpha - Drugs In Development, 2021

出版商 Global Markets Direct 商品編碼 557374
出版日期 內容資訊 英文 76 Pages
訂單完成後即時交付
價格
視黃酸受體Alpha:開發中產品分析 Retinoic Acid Receptor Alpha - Drugs In Development, 2021
出版日期: 2021年08月31日內容資訊: 英文 76 Pages
簡介

這份報告提供以視黃酸受體Alpha為標的之治療藥開發平台現狀及最新更新之各開發階段比較分析,提供涵括了最新的新聞和發表之企業和研究機關開發中治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

視黃酸受體Alpha;概要

視黃酸受體Alpha;治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:不同症狀
  • 企業開發中的產品

治療藥的評估

  • 各作用機制
  • 各給藥途徑
  • 各分子類型

開發治療藥的企業

  • 3SBio Inc
  • Io Therapeutics Inc
  • Phosphagenics Ltd
  • Sol-Gel Technologies Ltd

藥物簡介

暫停中的產品

開發中止的產品

產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC2942TDB

Summary:

Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA) pipeline Target constitutes close to 15 molecules. The latest report Retinoic Acid Receptor Alpha - Drugs In Development, 2021, outlays comprehensive information on the Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA) - Retinoic acid receptor alpha (RARA) is a nuclear receptor that is encoded by the RARA gene. RARA plays an essential role in the regulation of retinoic acid-induced germ cell development during spermatogenesis. It promotes the survival and development of early meiotic prophase spermatocytes. It regulates expression of target genes in a ligand-dependent manner by recruiting chromatin complexes containing KMT2E/MLL5 and mediates retinoic acid-induced granulopoiesis. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 2, 1, 5 and 4 respectively.

Report covers products from therapy areas Dermatology, Oncology, Immunology, Ophthalmology, Respiratory, Central Nervous System, Gastrointestinal, Genetic Disorders, Hematological Disorders, Infectious Disease, Male Health and Metabolic Disorders which include indications Acne Vulgaris, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Acute Promyelocytic Leukemia, Bronchopulmonary Dysplasia, Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type A, Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type B, Batten Disease, Breast Cancer, Germ Cell Tumors, Hand Dermatitis, Inflammatory Bowel Disease, Kaposi Sarcoma, Male Contraception, Mantle Cell Lymphoma, Multiple Myeloma (Kahler Disease), Myelodysplastic Syndrome, Neuroblastoma, Neutropenia, Psoriasis, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Retinopathy Of Prematurity, Sarcomas, Systemic Lupus Erythematosus and Type 1 Diabetes (Juvenile Diabetes).

Furthermore, this report also reviews key players involved in Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA)
  • The report reviews Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA) targeted therapeutics

Reasons to Buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA)Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

  • Introduction
  • Global Markets Direct Report Coverage
  • Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA) - Overview
  • Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA) - Companies Involved in Therapeutics Development
  • ABIONYX Pharma SA
  • Advent Therapeutics Inc
  • Avecho Biotechnology Ltd
  • Galephar Pharmaceutical Research Inc
  • Io Therapeutics Inc
  • Novartis AG
  • Orphagen Pharmaceuticals Inc
  • Orphanix GmbH
  • Ortho Dermatologics Inc
  • Polaryx Therapeutics Inc
  • Selphagy Therapeutics Inc
  • Sunny BioDiscovery Inc
  • TherapyX Inc
  • Toko Pharmaceutical Industries Co Ltd
  • Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA) - Drug Profiles
  • (benzoyl peroxide + tretinoin) - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • (gemfibrozil + tretinoin) - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • (TPX-6001 + tretinoin) - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • alitretinoin - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • alitretinoin - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • IRX-5183 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • OR-812 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • SBD-073 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecule to Agonize RAR Alpha and RXR Alpha for Acute Promyelocytic Leukemia - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Antagonize RAR Alpha for Opthamology - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • tamibarotene - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • tazarotene - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • tretinoin - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • tretinoin - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • tretinoin - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • vitamin A palmitate - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • vitamin A palmitate - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA) - Dormant Products
  • Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA) - Discontinued Products
  • Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA) - Product Development Milestones
  • Featured News & Press Releases
  • Aug 04, 2021: Health Canada approves ARAZLO (Tazarotene) Lotion, 0.045%, first such lotion treatment for acne vulgaris
  • Apr 21, 2021: Ortho Dermatologics to present abstract on ARAZLO (tazarotene) Lotion at 2021 American Academy of Dermatology Annual Meeting
  • Dec 05, 2020: Syros presents new data from Phase 2 clinical trial of SY-1425 and announces plans to initiate registration-enabling trial in MDS and randomized Phase 2 trial in AML
  • Nov 04, 2020: Syros to present new data from phase 2 clinical trial of SY-1425 in oral presentations at 62nd ASH annual meeting
  • Jul 23, 2020: Ortho Dermatologics launches ARAZLO (tazarotene) lotion, 0.045%, in the United States
  • Jun 23, 2020: Ortho Dermatologics launches ARAZLO (tazarotene) lotion, 0.045%, in the United States
  • Jan 13, 2020: Ortho Dermatologics announces publication of pivotal phase 3 data on ARAZLO (tazarotene) Lotion, 0.045% in the Journal of Drugs in Dermatology (JDD)
  • Jan 12, 2020: Syros announces new update on SY-1425
  • Dec 19, 2019: FDA approves Ortho Dermatologics' ARAZLO (Tazarotene) lotion, 0.045%, for acne vulgaris
  • Oct 24, 2019: Syros Announces new data from phase 2 trial of SY-1425 in combination with azacitidine demonstrating high response rates, rapid onset of action and favorable tolerability profile in RARA-Positive Newly Diagnosed Unfit AML Patients
  • Oct 15, 2019: Bausch Health's Ortho Dermatologics business to present data on tazarotene at The Fall Clinical Dermatology Conference
  • Oct 15, 2019: Bausch Health's Ortho Dermatologics business to present data on acne drug tretinoin at The Fall Clinical Dermatology Conference
  • Aug 07, 2019: Ortho Dermatologics announces U.S. FDA filing acceptance for IDP-123 treatment for Acne Vulgaris in lotion form
  • Aug 01, 2019: Syros highlights key accomplishments and provides milestone update on SY-1425
  • Jul 09, 2019: GSK's Alitoc becoming salvation treatment for chronic hand eczema patients
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

List of Tables

  • Number of Products under Development by Stage of Development, 2021
  • Number of Products under Development by Therapy Areas, 2021
  • Number of Products under Development by Indications, 2021
  • Number of Products under Development by Indications, 2021 (Contd..1)
  • Number of Products under Development by Companies, 2021
  • Products under Development by Companies, 2021
  • Products under Development by Companies, 2021 (Contd..1)
  • Number of Products by Stage and Mechanism of Actions, 2021
  • Number of Products by Stage and Route of Administration, 2021
  • Number of Products by Stage and Molecule Type, 2021
  • Pipeline by ABIONYX Pharma SA, 2021
  • Pipeline by Advent Therapeutics Inc, 2021
  • Pipeline by Avecho Biotechnology Ltd, 2021
  • Pipeline by Galephar Pharmaceutical Research Inc, 2021
  • Pipeline by Io Therapeutics Inc, 2021
  • Pipeline by Novartis AG, 2021
  • Pipeline by Orphagen Pharmaceuticals Inc, 2021
  • Pipeline by Orphanix GmbH, 2021
  • Pipeline by Ortho Dermatologics Inc, 2021
  • Pipeline by Polaryx Therapeutics Inc, 2021
  • Pipeline by Selphagy Therapeutics Inc, 2021
  • Pipeline by Sunny BioDiscovery Inc, 2021
  • Pipeline by TherapyX Inc, 2021
  • Pipeline by Toko Pharmaceutical Industries Co Ltd, 2021
  • Dormant Products, 2021
  • Dormant Products, 2021 (Contd..1)
  • Discontinued Products, 2021

List of Figures

List of Figures

  • Number of Products under Development by Stage of Development, 2021
  • Number of Products under Development by Therapy Areas, 2021
  • Number of Products under Development by Top 10 Indications, 2021
  • Number of Products by Mechanism of Actions, 2021
  • Number of Products by Stage and Mechanism of Actions, 2021
  • Number of Products by Routes of Administration, 2021
  • Number of Products by Stage and Routes of Administration, 2021
  • Number of Products by Molecule Types, 2021
  • Number of Products by Stage and Molecule Types, 2021